Holen Sie sich die Stockscreener-App
0.7849
0.99%
0.0077
Schlusskurs vom Vortag:
$0.7772
Offen:
$0.7722
24-Stunden-Volumen:
60,193
Relative Volume:
0.61
Marktkapitalisierung:
$20.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.22M
KGV:
-0.4424
EPS:
-1.7742
Netto-Cashflow:
$-17.31M
1W Leistung:
-8.21%
1M Leistung:
-25.25%
6M Leistung:
-6.11%
1J Leistung:
+46.99%
1-Tages-Spanne:
$0.77
$0.8108
1-Wochen-Bereich:
$0.7521
$0.8807
52-Wochen-Spanne:
$0.53
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.77 | 20.45M | 0 | -39.22M | -17.31M | -1.7742 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Q4 2025 Earnings: Deep EPS Miss Amid Pre-Revenue StageEarnings Per Share - Newser
AEON Biopharma Q4 2025 Earnings: Major EPS Miss and No Revenue Weigh on Investor SentimentEarnings Expansion Phase - Newser
AEON Biopharma Inc. (AEON) Q4 2025 Earnings: Significant EPS Miss and Stock Decline Amid Development ChallengesHigh Growth Earnings - Newser
AEON Biopharma Dips 2.74% as Stock Nears Critical Support at $0.76Watchlist Stock Ideas - Newser
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma shares fall over 2% on quarterly loss - Investing.com
AEON Biopharma shares fall over 2% on quarterly loss By Investing.com - Investing.com South Africa
AEON Biopharma Reports Q1 Financial Results - Intellectia AI
AEON Biopharma Releases Updated Investor Relations Presentation - TipRanks
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma (AEON) releases May 2026 corporate investor presentation via Form 8-K - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AEON Biopharma (NYSE: AEON) Q1 2026 loss, financing deals and going concern risk - Stock Titan
AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut - Stock Titan
AEON’s Botox biosimilar plan gets FDA feedback as debt falls 90% - Stock Titan
TradingKey - TradingKey
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
AEON Biopharma Sets Annual Shareholder Meeting - The Manila Times
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON Bio (AEON) Stock: Why Brand Strength (Eye on Rally) 2026-04-20Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
What is the bull case for AEON Bio (AEON) Stock | AEON Q4 2025 Earnings: AEON Biopharma Inc. misses EPS, no revenue postedPre-Earnings Drift - Newser
Is AEON Bio (AEON) Stock Rebounding | Price at $0.90, Up 1.27%Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - The Globe and Mail
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Singapore
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
New AEON finance chief gets stock awards tied to NYSE compliance - Stock Titan
Form 8-KCurrent report - ADVFN
AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan
AEON Q4 2025 Earnings: AEON Biopharma Inc. Posts Big EPS Miss, No Revenue - Newser
AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma 2025 Financial Review - AlphaStreet
Stock Market Recap: Whats the profit margin of AEON Biopharma Inc - baoquankhu1.vn
AEON Biopharma reports biosimilar progress, secures financing By Investing.com - Investing.com Australia
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - The Manila Times
Can AEON Biopharma Inc keep up with sector leaders2026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
Kapitalisierung:
|
Volumen (24h):